Market Place
Sourcing Support
Guardant Health To Report Q3 2024 Financial Results On November 6
15 Oct 2024 //
BUSINESSWIRE
Guardant Health to Participate in Upcoming Investor Conferences
08 Aug 2024 //
BUSINESSWIRE
FDA Approves Guardant Health`s Shield™ Blood Test For CRC Screening
29 Jul 2024 //
BUSINESSWIRE
Guardant`s Blood Cancer Test Nears Medicare Coverage With FDA Approval
29 Jul 2024 //
REUTERS
Guardant To Present Blood Test RWD Studies At ASCO 2024
30 May 2024 //
BUSINESSWIRE
FDA panel gives OK to Guardant`s colorectal cancer blood test
23 May 2024 //
FIERCE BIOTECH
Guardant Health to Participate in Upcoming Investor Conferences
22 May 2024 //
BUSINESSWIRE
US FDA staff says Guardant`s test may fail to detect some pre-cancerous tumors
22 May 2024 //
REUTERS
Guardant Gets EU IVDR Cert For Guardant360 CDx Liquid Biopsy
21 May 2024 //
BUSINESSWIRE
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Guardant To Present Shield CRC Screening Blood Test Data
16 May 2024 //
BUSINESSWIRE
Guardant preps for FDA review of colorectal cancer blood test
13 May 2024 //
FIERCE BIOTECH
Guardant Health Q1 2024 Results, Increases 2024 Revenue Guidance
09 May 2024 //
BUSINESSWIRE
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
07 May 2024 //
BUSINESSWIRE
Guardant Health to Participate in Upcoming Investor Conferences
07 May 2024 //
BUSINESSWIRE
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
18 Apr 2024 //
BUSINESSWIRE
Guardant Health to Present Data of Epigenomics at 2024 AACR Annual Meeting
03 Apr 2024 //
BUSINESSWIRE
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Guardant Health to Participate in Upcoming Investor Conferences
15 Feb 2024 //
BUSINESSWIRE
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results
01 Feb 2024 //
BUSINESSWIRE
Guardant Health and Hikma Partner to Offer Cancer Screening Tests
08 Jan 2024 //
BUSINESSWIRE
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
08 Jan 2024 //
BUSINESSWIRE
Guardant Announces $90.7 Million Registered Direct Offering with Baillie Gifford
21 Dec 2023 //
BUSINESSWIRE
Guardant to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
BUSINESSWIRE
Guardant Announces Tentative Date of Panel Review of Shield Blood Test
19 Dec 2023 //
BUSINESSWIRE
Cancer Research UK and Guardant Health Launch Collaboration
04 Dec 2023 //
BUSINESSWIRE
Guardant Health launches Shield blood-based screening test for colorectal cancer
12 Nov 2023 //
PR NEWSWIRE
Guardant Health Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Singapore approves Guardant360 CDx blood testfor patients advanced solid cancers
30 May 2023 //
BIOSPECTRUM ASIA
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
22 May 2023 //
BUSINESSWIRE
Guardant Health Reports First Quarter 2023 Financial Results
09 May 2023 //
BUSINESSWIRE
Guardant`s colon cancer test on par with other screenings: study
09 May 2023 //
FIERCE BIOTECH
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Guardant and AnHeart Announce Collaboration to Develop Guardant360 CDx
02 Feb 2023 //
BUSINESSWIRE
Guardant Health receives FDA approval for Guardant360 CDx
30 Jan 2023 //
BUSINESSWIRE
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
09 Jan 2023 //
BUSINESSWIRE
Guardant DNA blood test finds 83% of colorectal cancers in trial,shares fall 35%
15 Dec 2022 //
REUTERS
Guardant Health Announces Collaboration With AZ to Develop Companion Diagnostic
08 Dec 2022 //
BUSINESSWIRE
Merck and Guardant expand partnership to develop cancer therapies
01 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Foghorn co-founder resigns from board; Guardant and Merck KGaA team up again
01 Sep 2022 //
ENDPTS
Guardant, Merck KGaA expand precision oncology collab
01 Sep 2022 //
FIERCEBIOTECH
Guardant Health Expands Strategic Collaboration With Merck KGaA
31 Aug 2022 //
BUSINESSWIRE
Guardant Health Expands Use of Guardant Reveal Liquid Biopsy Test
15 Aug 2022 //
BUSINESSWIRE
Guardant Health Receives FDA Approval for Guardant360® CDx as Diagnostic
12 Aug 2022 //
BUSINESSWIRE
Guardant Health & Blueprint Medicines present real-world data at IASLC 2022
08 Aug 2022 //
BUSINESS WIRE
Guardant Health Announces Data from Portfolio of Blood Tests and GuardantINFORM
05 Aug 2022 //
BUSINESSWIRE
Guardant takes cancer blood tests to China via lab partnership
06 Jul 2022 //
FIERCEBIOTECH
Guardant Health, Adicon announce strategic partnership for new cancer therapies
06 Jul 2022 //
PRNEWSWIRE
As lawsuit carries on against Guardant Health, CFO shakeup hits Illumina; & more
16 Jun 2022 //
ENDPTS
Guardant Health fires back at Illumina suit, claiming retaliation
27 May 2022 //
ENDPTS
Guardant Health to Participate in Upcoming June Investor Conferences
26 May 2022 //
BUSINESSWIRE
Guardant Health Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Guardant debuts first colorectal cancer screening blood test
02 May 2022 //
FIERCEBIOTECH
Guardant Health Presents New Data in Detecting Multiple Cancers at AACR
11 Apr 2022 //
BUSINESSWIRE
Illumina sues Guardant Health, former employees over stolen company secrets
19 Mar 2022 //
ENDPTS
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
14 Mar 2022 //
BUSINESSWIRE
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext Test
08 Mar 2022 //
BUSINESSWIRE
Guardant Health Reports Q4 2021 Financial Results and Provides 2022 Outlook
23 Feb 2022 //
BUSINESSWIRE
